Drug Profile


Alternative Names: FS-0101; Sifuvirtide injection; Sifuvirtide microbicide

Latest Information Update: 16 Jun 2016

Price : $50

At a glance

  • Originator FusoGen Pharmaceuticals
  • Class Antivirals; Peptides
  • Mechanism of Action HIV fusion inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II HIV infections

Most Recent Events

  • 25 Jun 2015 Sifuvirtide is still in preclinical trials for HIV infections (Prevention) in China (Topical)
  • 25 Jun 2015 Sifuvirtide is still in phase II trials for HIV infections in China (SC)
  • 01 Aug 2010 Safety and efficacy data from four completed phase I-II trials released by FusoGen Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top